Trump’s Return Could Benefit Indian Drugmakers With New Policy Favouring India Over China

Indian pharmaceutical companies don’t anticipate significant changes – having already experienced Trump’s presidency – but the US Biosecure Act presents a huge opportunity.

Leave a Reply

Your email address will not be published. Required fields are marked *